Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ACTR1B Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA518274
Description
This antibody is predicted to react with bovine, canine, mouse and rat based on sequence homology. This antibody is tested in Peptide ELISA: antibody detection limit dilution 128,000.
This gene encodes a 42.3 kD subunit of dynactin, a macromolecular complex consisting of 10 subunits ranging in size from 22 to 150 kD. Dynactin binds to both microtubules and cytoplasmic dynein and is involved in a diverse array of cellular functions, including ER-to-Golgi transport, the centripetal movement of lysosomes and endosomes, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. This subunit, like ACTR1A, is an actin-related protein. These two proteins, which are of equal length and share 90% amino acid identity, are present in a constant ratio of approximately 1:15 in the dynactin complex.
Specifications
ACTR1B | |
Polyclonal | |
Unconjugated | |
Actr1b | |
2310066K23Rik; AA960180; Actin-related protein 1B; Actr1b; AI851923; ARP1; ARP1 actin-related protein 1 homolog B, centractin beta; ARP1 actin-related protein 1 homolog B, centractin beta (yeast); ARP1 actin-related protein 1B, centractin beta; Arp1b; Beta-centractin; centractin beta; CTRN2; PC3; yeast homolog B | |
Goat | |
Ammonium Sulfate Precipitation | |
RUO | |
10120 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
0.5 mg/mL | |
TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
P42025 | |
Actr1b | |
Synthetic peptide sequence (YEEDGSRAIHRKT) corresponding to the C-terminus amino acids of ACTR1B (aa 363-376). | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction